29 Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability 1 Figure 2: Stacked diagram showing the trend of predicted drooling quotient (DQ) and visual analogue scale (VAS) per injection. Baseline is represented as the predicted reduction and predicted outcome combined. Predicted (adjusted) baseline values across all three injections were 26.7 and 74.3 for drooling quotient and VAS respectively. Level of significance: ap<0.05; bp<0.005 Significant predictors for both drooling quotient and VAS were baseline and age. Namely, a higher baseline drooling quotient or VAS predicted a higher outcome (drooling quotient and VAS) after 8 weeks, as well as a greater reduction in drooling quotient and VAS, and a higher age was associated with less reduction in both drooling quotient and VAS. The degree of motor disability predicted VAS; nonambulant children (defined by a Gross Motor Function Classification System level of IV or higher) have a greater reduction in VAS than ambulant children. No association was found for sex, developmental age, cerebral palsy, and epilepsy. The 8-week assessment of the drooling quotient and VAS after the second injection and the VAS after the third injection were slightly but significantly higher than after the first injection (Fig. 1). The second and third VAS baselines were significantly lower than the first VAS baseline. In case of drooling quotient, only the second
RkJQdWJsaXNoZXIy MjY0ODMw